title: Drug persistence and compliance affect patient-reported outcomes in overactive bladder syndrome.
abstract: To evaluate persistence and compliance for patients receiving antimuscarinics for overactive bladder (OAB), and to assess patient-reported outcomes (PROs) according to persistence and compliance.
  
  
  
  This was a 24-week, multicenter, prospective, observational study that included 952 OAB patients who had newly started antimuscarinics. Patients aged ≥18 years with a total OAB Symptom Score (OABSS) ≥3 and an urgency score of OABSS ≥2 were eligible for the study. Drug persistence and compliance were evaluated at 4, 12, and 24 weeks. Changes in scores on PROs were compared between groups (persistence vs. non-persistence and compliance vs. non-compliance) after 24 weeks. Factors contributing to persistence were examined using multivariate logistic regression.
  
  
  
  After 24 weeks, 56.8 % of patients remained on treatment. The persistence rates were 85.6 and 71.4 % after 4 and 12 weeks, respectively. The compliance rates were 75.6, 53.8, and 34.3 % after 4, 12, and 24 weeks, respectively. Patients who were persistent in taking antimuscarinics resulted in significant improvements in OABSS and OAB questionnaire short form score compared with those who were non-persistent (all p < 0.05). Changes from baseline in OABSS (p = 0.735) and the EuroQoL five-dimensions score (p = 0.384) were not significantly different between compliant and non-compliant groups. Predictors of high persistence included older age (OR 1.017, p = 0.007) and dry OAB (OR 1.422, p = 0.013).
  
  
  
  Patients who were persistent with antimuscarinics showed significant improvements in PROs compared to those who were non-persistent.
authors.affiliation: Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, #81 Irwon-ro, Gangnam-gu, Seoul, 135-710, Republic of Korea.
authors.forename: Tae Heon
authors.initials: TH
authors.lastname: Kim
authors.affiliation: Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
authors.forename: Myung-Soo
authors.initials: MS
authors.lastname: Choo
authors.affiliation: Corporate Affairs & Health and Value, Pfizer Pharmaceutical Korea Ltd., Seoul, Republic of Korea.
authors.forename: Young-Joo
authors.initials: YJ
authors.lastname: Kim
authors.affiliation: Corporate Affairs & Health and Value, Pfizer Pharmaceutical Korea Ltd., Seoul, Republic of Korea.
authors.forename: Hyein
authors.initials: H
authors.lastname: Koh
authors.affiliation: Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, #81 Irwon-ro, Gangnam-gu, Seoul, 135-710, Republic of Korea. ksleedr@skku.edu.|Department of Medical Device Management and Research, SAIHST, Sungkyunkwan University, Seoul, Republic of Korea. ksleedr@skku.edu.
authors.forename: Kyu-Sung
authors.initials: KS
authors.lastname: Lee
mesh_terms: D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010349:Patient Compliance; D000071066:Patient Reported Outcome Measures; D011446:Prospective Studies; D011788:Quality of Life / Q000523:psychology*; D011795:Surveys and Questionnaires; D016896:Treatment Outcome; D053201:Urinary Bladder, Overactive / Q000188:drug therapy*
keywords: Antimuscarinic agents; Overactive bladder; Patient outcome assessment; Persistence